|Videos|October 16, 2019

What to Expect in October's Emerging/Re-emerging Infections Section of Contagion&reg

Hermione Hurley, MD, MCBhB, previews her October cover story for Contagion on the intersection between the opioid epidemic and infectious disease

Segment Description: Hermione Hurley, MD, MCBhB, physician with Denver Health & Hospital Authority, previews her October cover story for Contagion® on the intersection between the opioid epidemic and infectious disease.

Interview transcript: (modified slightly for readability)

Dr. Hurley: In this October issue of Contagion®, Drs. Rowan, Al-Tayyib, and myself speak about the role that the rising rates of infectious disease associated with substance use and particularly opioid and injection use in America. And we also talk about how it's a call to action for ID physicians. We think it has an important role to play in HIV and hepatitis C elimination. We try and give people hope that ID physicians are in a good position to help with these really important issues.

I think it can feel easy to be overburdened and have a lot to do in each particular session. I was concerned about that before I started incorporating infectious disease and substance use into my practice. But I've actually found that using both techniques, even in a single sitting, really has made my job more rewarding and it's really helped both my patients and clients alike. I want people to be hopeful to make a start, to make a start on an individual level and then move towards your system, move towards your state, move towards your nation, but be hopeful that we have an important role to play as providers.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.